| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
June 21, 2023 |
|
|
| |
|
|
| |
|
|
|
Xtalks, online
2023 -7-19
Since the first oligonucleotide (OGNT) drug was approved by the US Food and Drug Administration (FDA) for clinical use in 1998, the industry has made significant progress in the advancement of techniques, technology and development methods; however, due to the complexity and sensitivity of oligonucleotides, there are still challenges to navigate and overcome within drug development and bioanalytical analysis.
Join this webinar to learn about the current and future state of oligonucleotides from a bioanalytical industry expert as they discuss:
Current and future state of the bioanalysis of oligonucleotides
Common approaches to bioanalysis of oligonucleotides
Evaluating and selecting the optimal and strategic approach
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Troy Voelker, PhD, Director of Laboratory Operations, Aliri
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -7-19
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|